VistaGen Therapeutics, Inc. (NASDAQ:VTGN) is one of the stocks that are taking the center stage today as the company shares are trading 11.16% or 0.061 points lower from last closing price of $0.55, reaching $0.4886 at last check. So what’s going on with VTGN shares anyway? The price has dropped in 3 of the last 5 days and is down -15.87% over the past week. It will be exciting to see whether the stock manages to continue decreasing or take a minor break for the next few days. The move came on weak volume too with far less shares changing hands than in a normal session. Trading activity as of this writing weakened by -35,235 shares, and in total 82365 shares valued at $40244 were seen changing hands compared with 117600 shares valued at $64680 recorded at the previous session. You should take into consideration that a falling volume on lower prices shows the bearish trend but this is an early indication which means that the VTGN stock is near its bottom.
VistaGen Therapeutics, Inc. (VTGN) shares have notched a 3-month decline of about -15.87%, but has still tumbled -64.67% year to date. By comparison, the stock sank -58.59% over the past 12 months, while it slipped -19.56% over the 1 month. The company’s market cap is around $24.41M, with its short interest ratio standing at 5.91%.
In the current trading session for VTGN, the stock witnessed two major price actions, it rose to a high of $0.525 and was down as much as $0.4822 at one point. The high recorded is very low when compared to their 52-week high which is $0.38. The 52-week high is now at -79.51 distance from current price. Their recent low of $2.44 represents a 31.54% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for VTGN is $2.35, this is below the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.
The company recorded an interesting insider purchase transaction by the Director on Mar 13, 2019. A Securities and Exchanges Commission filings show that Jon S Saxe bought a total of 12,080 VTGN shares that day for a sum of around $15,221. The filings show that the insider stake has now grown to 3,251 shares, currently worth $1,588. VistaGen Therapeutics, Inc. (VTGN) insiders have acquired no shares in the stock within the past three months. The total insider sales reported to the SEC in that time frame amounted to shares. In total, individual insiders traded no shares in the business, which makes up 0% of 20,000 shares that were traded over a year. In the past 12 months, insiders have purchased 20,000 shares while the seller parted with shares.
VTGN‘s last price was down -58.77% as compared to the average trading price of 50 days recorded at $1.19 while enlarging the period to 200 trading days, the average closing price was $0.65. At present, there are 46.05 million in the total number of common shares owned by the public and among those 37.56 million shares have been available to trade. The percentage of shares being held by the company management was 0.2% while institutions stake was 20.5%. The company has generated negative returns on equity over the last 12 months (-644.7%). It managed to keep its gross profit margin at 0% over the past 12 months.
When assessing the full upside of the VTGN stock, there is another set of technicals that should be looked into and considered. Its -8.9% decline from moving average of $0.54 has brought about a negative sentiment when calculated over the last 20 days. The market has allocated a beta of -0.56 to the stock. With the beta been less than one, this implies that the company shares are theoretically less volatile than the market, something that the traders definitely are keeping an eye on.
Most of the analysts surveyed by Thomson/First Call think quite highly of VistaGen Therapeutics, Inc. — 2 analysts rate the stock as a buy with another 0 rating it strong buy. There are 1 analysts who maintain a hold rating for the stock, with 0 giving it a sell rating. Analysts arrived at a 12-month price target of $4.2333 on shares of VistaGen Therapeutics, Inc. (NASDAQ:VTGN), which corresponds to 763.95% upside potential than its current market price of $0.4886 and implies potential despite the recent drop in the price. However, their current target price has fallen from $6 a month ago and is down handily from the consensus target of $10 a quarter ago.
In the last five years, the EPS of the company has been roughly 19.7%. Though the percentage looks encouraging, extra headwinds are emerging as looking out over a next 5-year period, with analysts estimating that their earnings will decrease annually by 0%. The revenue of the company has retreated at an average annualized rate of about 0 over the last five years. The company recently recorded a drop of 0%, but this figure is rather unattractive.
Let’s briefly check the hedge fund interest towards VTGN stock. Vanguard Group Inc. added position in the company after it grew 3.1% or 1,160,214 shares of its common stock. The hedge fund now owns 1,196,181 shares worth $584,454, SEC documents show. HighTower Advisors LLC shored up assets in the stock as 31046.92 shares have been purchased, increasing its stake by 326.3% to 132,353 shares which are currently valued at $64,668. In addition, D.A. Davidson & CO. recently reported that it now owns 82,500 shares making a total of $40,310 based on the recent price. This refelects a change of -27.9% in their ownership.